Protective effects of erythropoietin on endotoxin-related organ injury in rats

Abstract

The protective effect of erythropoietin (EPO) on tissues following ischemia and reperfusion injuries remains poorly understood. We aimed to investigate the effect of EPO in preventing endotoxin-induced organ damage. Rat model of multiple organ failure (MOF) was established by tail vein injection of 10 mg/kg lipopolysaccharide (LPS). Recombinant human EPO treatment (5000 U/kg) was administered by tail vein injection at 30 min after LPS challenge. Twenty-four h after EPO treatment, changes in serum enzyme levels, including aspartate aminotransferase (AST), alanine transaminase (ALT), blood urea nitrogen (BUN) and creatinine (Cr), were evaluated by biochemical analysis. Serum levels of tumor necrosis factor-α (TNF-α) were determined by using immunoradiometric assay. Histological examination of tissue sections was carried out by hematoxylin and eosin staining, while ultrastructure evaluation of organ tissues was assessed by transmission electron microscopy. Protein expression levels were detected by using Western blotting. EPO treatment showed a modest effect in preventing LPS-induced elevation of AST, ALT, BUN, Cr, and TNF-α levels, and in protecting against LPS-induced tissue degeneration and injured ultrastructure in the lung, liver, and kidney. Moreover, LPS promoted phosphorylation of alanine aminotransferase (AKT) and increased nuclear factor-κB (NF-κB) activation in the lung, liver, and kidney (P<0.05 vs. control). However, EPO treatment significantly decreased the LPS-induced pAKT up-regulation in these tissues (P<0.05 vs. LPS treatment alone). The present study demonstrates that EPO may play a protective role against LPS-induced MOF by reducing the inflammatory response and tissue degeneration, possibly via the phosphatidylinositol 3-kinase/AKT and NF-κB signaling pathways.

Keywords

erythropoietin / lipopolysaccharide / multiple organ injury

References

[1] AngusDC, Linde-ZwirbleWT, LidickerJ, et al.. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001, 29(7): 1303-1310

[2] MorrisonDC, UlevitchRJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol, 1978, 93(2): 526-618

[3] YoshikawaT, TakanoH, TakahashiS, et al.. Changes in tissue antioxidant enzyme activities and lipid peroxides in endotoxin-induced multiple organ failure. Circ Shock, 1994, 42(1): 53-58

[4] ThiemermannC, RuettenH, WuCC, et al.. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol, 1995, 116(7): 2845-2851

[5] KosaiK, MatsumotoK, FunakoshiH, et al.. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology, 1999, 30(1): 151-159

[6] MiyajiT, HuX, YuenPS, et al.. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int, 2003, 64(5): 1620-1631

[7] PatelNS, SharplesEJ, CuzzocreaS, et al.. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int, 2004, 66(6): 983-989

[8] GrimmC, WenzelA, GroszerM, et al.. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med, 2002, 8(7): 718-724

[9] CalapaiG, MarcianoMC, CoricaF, et al.. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol, 2000, 401(3): 349-356

[10] KouryST, BondurantMC, KouryMJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood, 1988, 71(2): 524-527

[11] MaxwellPH, OsmondMK, PughCW, et al.. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int, 1993, 44(5): 1149-1162

[12] BrowneJK, CohenAM, EgrieJC, et al.. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol, 1986, 51(Pt1): 693-702

[13] YoshimuraA, MisawaH. Physiology and function of the erythropoietin receptor. Curr Opin Hematol, 1998, 5(5): 171-176

[14] OberhoffC, NeriB, AmadoriD, et al.. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, con trolled study. Ann Oncol, 1998, 9(3): 255-260

[15] EhrenreichH, HasselblattM, DembowskiC, et al.. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med, 2002, 8(8): 495-505

[16] BrendtP, FreyU, AdamzikM, et al.. Darbepoetin alpha, a long-acting erythropoeitin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-alpha. Shock, 2009, 31(1): 50-54

[17] SpreerA, GerberJ, HanssenM, et al.. No neuroprotective effect of erythropoietin under clinical treatment conditions in a rabbit model of Escherichia coli meningitis. Pediatr Res, 2007, 62(6): 680-683

[18] SinclairAM, CoxonA, McCafferyI, et al.. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood, 2010, 115(21): 4264-4272

[19] SøllingC. Organ-protective and immunomodulatory effects of erythropoietin-An update on recent clinical trials. Basic Clin Pharmacol Toxicol, 2012, 110(2): 113-121

[20] JiaCS, ChenAJ, RenLQ. Effects of selenium and vitamin E on myocardial fibrosisin rats fed on grains from Keshan disease endemic area. Jilin Daxue Xuebao (Yixue Ban) (Chinese), 2011, 37(3): 309-310

[21] HouYC, ChiuWC, YehCL, et al.. Glutamine modulates lipopolysaccharide-induced activation of NF-kappaB via the Akt/mTOR pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2012, 302(1): L174-L183

[22] AbrahamE. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis, 2003, 187(Suppl2): S364-S369

[23] BrinesML, GhezziP, KeenanS, et al.. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 2000, 97(19): 10526-10531

[24] BianchiR, BuyukakilliB, BrinesM, et al.. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA, 2004, 101(3): 823-828

[25] GongH, WangW, KwonTH, et al.. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int, 2004, 66(2): 683-695

[26] ParsaCJ, KimJ, RielRU, et al.. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem, 2004, 279(20): 20655-20662

[27] ParsaCJ, MatsumotoA, KimJ, et al.. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest, 2003, 112(7): 999-1007

[28] AbdelrahmanM, SharplesEJ, McDonaldMC, et al.. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock, 2004, 22(1): 63-69

[29] WestenfelderC, BiddleDL, BaranowskiRL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int, 1999, 55(3): 808-820

[30] Beleslin-CokicBB, CokicVP, WangL, et al.. Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. Cytokine, 2011, 54(2): 129-135

[31] ElliottS, BusseL, SwiftS, et al.. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant, 2012, 27(7): 2733-2745

[32] HaseyamaY, SawadaK, OdaA, et al.. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood, 1999, 94(5): 1568-1577

[33] CarvalhoG, LefaucheurC, CherbonnierC, et al.. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene, 2005, 24(5): 737-745

[34] SharplesEJ, ThiemermannC, YaqoobMM. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol, 2006, 6(2): 184-189